An Expanded Access Program (EAP) for the use of PLX-PAD cells to treat Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19
Latest Information Update: 03 Apr 2023
At a glance
- Drugs Emiplacel (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- Sponsors Pluri
- 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
- 04 Sep 2020 New trial record
- 27 Aug 2020 According to a Pluristem Therapeutics media release, the U.S. Food and Drug Administration (FDA) has cleared this program. Data from this program will be collected and evaluated alongside company's clinical trial.